证券代码：600774 证券简称：汉商集团 编号：2025-020 汉商集团股份有限公司 2024 年度利润分配预案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 汉商集团股份有限公司（以下简称"公司"）2024 年度利润分配方案为：不进行 现金分红，不送红股，不以资本公积转增股本。 公司 2024 年度利润分配方案已经公司第十二届董事会第三次会议审议通过，尚需 提交 2024 年年度股东大会审议。 公司未触及《上海证券交易所股票上市规则》（以下简称《股票上市规则》）第 9.8.1 条第一款第（八）项规定的可能被实施其他风险警示的情形。 一、利润分配方案 （一）利润分配方案的具体内容 经中审众环会计师事务所（特殊普通合伙）出具的 2024 年度《审计报告》， 公司 2024 年度实现归属于上市公司股东的净利润为人民币-14,587,166.58 元， 截至 2024 年 12 月 31 日，母公司期末可供分配利润为人民币 365,880,259.63 元。经董事会决议，2024 年度利润分配方案为：不进行 ...

证券代码：600774 股票简称：汉商集团 编号：2025-024 汉商集团股份有限公司 关于提请股东大会授权董事会办理 以简易程序向特定对象发行股票相关事宜的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司证券发行注册管理办法》《上海证券交易所上市公司证券发 行上市审核规则》《上海证券交易所上市公司证券发行与承销业务实施细则》等 有关法律、法规、规章及规范性文件的规定，汉商集团股份有限公司（以下简称 "公司"）于 2025 年 4 月 29 日分别召开第十二届董事会第三次会议和第十二届 监事会第二次会议，提请 2024 年年度股东大会授权董事会办理以简易程序向特 定对象发行股票，融资总额不超过人民币 3 亿元且不超过最近一年末净资产的 20%（以下简称"本次发行"），授权期限自 2024 年年度股东大会审议通过之日起 至 2025 年年度股东大会召开之日止。具体情况如下： 一、本次授权的具体内容 （一）确认公司是否符合以简易程序向特定对象发行股票条件 授权董事会根据《中华人民共和国公司法》《中华人民共和国 ...

关于汉商集团股份有限公司 2024 年度营业收入扣除情况表 的专项审核报告 众环专字(2025) 0101065 号 目 录 起始页码 1 专项审核报告 汇总表 汉商集团股份有限公司 2024 年度营业收入扣除情况表 1 关于汉商集团股份有限公司 2024 年度营业收入扣除情况表 的专项核查报告 众环专字(2025) 0101065号 汉商集团股份有限公司全体股东: 我们接受委托,在审计了汉商集团股份有限公司(以下简称"汉商集团")2024年12月 31 日的合并及公司的资产负债表,2024年度合并及公司的利润表、合并及公司的现金流量 表和合并及公司的股东权益变动表以及财务报表附注(以下简称"2024 年度财务报表")的 基础上,对后附的《汉商集团股份有限公司 2024年度营业收入扣除情况表》(以下简称"营 业收入扣除表")进行了专项核查。 按照《上海证券交易所股票上市规则》及《上海证券交易所上市公司自律监管指南第2 号 -- 业务办理》的规定,编制和披露营业收入扣除表,提供真实、合法、完整的核查证据, 是汉商集团管理层的责任。我们的责任是在执行核查工作的基础上对营业收入扣除表发表专 项核查意见。 我们按照中 ...

汉商集团股份有限公司 审计报告 众环审字(2025) 0103180号 目 景 审计报告 | 财务报表 | | | --- | --- | | 合并资产负债表 | | | 合并利润表 | 3 | | 合并现金流量表 | 4 | | 合并股东权益变动表 | 5 | | 资产负债表 | 7 | | 利润表 | | | 现金流量表 | 10 | | 股东权益变动表 | 11 | | 财务报表附注 | 13 | 起始页码 众环审字(2025)0103180 号 汉商集团股份有限公司全体股东: 审计意见 í 我们审计了汉商集团股份有限公司(以下简称"汉商集团")财务报表,包括 2024年 12 月 31 日的合并及公司资产负债表,2024年度的合并及公司利润表、合并及公司现金流量表、 合并及公司股东权益变动表以及相关财务报表附注。 我们认为,后附的财务报表在所有重大方面按照.企业会计准则的规定编制,公允反映了 汉商集团 2024年 12月 31 日合并及公司的财务状况以及 2024 年度合并及公司的经营成果 和现金流量。 I Í 形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册会 ...

关于汉商集团股份有限公司 内部控制审计报告 众环专字(2025) 0103181 号 目 景 起始页码 1 内部控制审计报告 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指 引》的规定,建立健全和有效实施内部控制,并评价其有效性是汉商集团公司董事会的责任。 内部控制审计报告 众环审字(2025)0103181 号 汉商集团股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计了汉 商集团股份有限公司(以下简称"汉商集团")2024年12月 31 目的财务报告内部控制的有 效性。 一、汉商集团对内部控制的责任 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审计意见, 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于情况的变化 可能导致内部控制变得不恰当,或对控制政策和程序遵循的程度降低,根据内部控制审计结 果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为,汉商集团股份有限公 ...

汉商集团股份有限公司 二〇二四年度独立董事述职报告 ——独立董事 胡迎法 1、出席会议情况 2024 年，公司共召开了 7 次董事会会议，包括 2 次现场会议和 5 次通讯 会议，本人均亲自出席；本人会议出席率和参与决议事项表决率均为 100%。本 人认真审议提交董事会的议案，以谨慎的态度行使表决权，认为公司在 2024 年 度召开的董事会符合法定程序，重大经营决策事项和其它重大事项均履行了相 关程序，会议程序及所作决议合法有效，本人对年度内审议的董事会议案均投 了赞成票。 作为汉商集团股份有限公司（"汉商集团"或"公司"）的独立董事，本 人严格按照《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上海证券交易所股票上 市规则》（"《上交所上市规则》"）、《上市公司独立董事管理办法》等法 律法规和规范性文件的规定，以及汉商集团《公司章程》《独立董事工作制 度》等规定，切实履行独立董事忠实勤勉义务，积极为公司经营发展建言献 策，努力维护公司利益及全体股东特别是中小股东的合法权益。现将本人 2024 年度履行职责的具体情况报告如下： 一、独立董事基本情况 ...

汉商集团股份有限公司 二〇二四年度独立董事述职报告 ——独立董事 古继洪 作为汉商集团股份有限公司（"汉商集团"或"公司"）的独立董事，本 人严格按照《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上海证券交易所股票上 市规则》（"《上交所上市规则》"）、《上市公司独立董事管理办法》等法 律法规和规范性文件的规定，以及汉商集团《公司章程》《独立董事工作制 度》等规定，切实履行独立董事忠实勤勉义务，积极为公司经营发展建言献 策，努力维护公司利益及全体股东特别是中小股东的合法权益。现将本人 2024 年度履行职责的具体情况报告如下： 一、独立董事基本情况 本人履职后公司董事会审计委员会举行了 1 次会议，本人作为审计委员会 主任委员亲自出席。本人认真履行审计委员会的工作职责，参与和跟进了公司 定期报告的编制工作，审议通过了公司按照会计准则编制的财务报告等议案。 1、工作履历、专业背景及兼职情况 古继洪，男，1963 年 12 月出生，中共党员，博士研究生，正高级会计 师。1983 年 8 月至 2001 年 5 月，在铁道部大桥工程局四处工作，历任会计 ...

汉商集团股份有限公司 二〇二四年度独立董事述职报告 ——独立董事 胡浩 作为汉商集团股份有限公司（"汉商集团"或"公司"）的独立董事，本 人严格按照《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上海证券交易所股票上 市规则》（"《上交所上市规则》"）、《上市公司独立董事管理办法》等法 律法规和规范性文件的规定，以及汉商集团《公司章程》《独立董事工作制 度》等规定，切实履行独立董事忠实勤勉义务，积极为公司经营发展建言献 策，努力维护公司利益及全体股东特别是中小股东的合法权益。现将本人 2024 年度履行职责的具体情况报告如下： 一、独立董事基本情况 1、工作履历、专业背景及兼职情况 胡浩，男，1981 年 9 月出生，中共党员，研究生学历，硕士学位。2004 年-2008 年任滁州职业技术学院财务管理系讲师，2008 年至今历任宇业集团有 限公司董事长秘书，项目公司总经理。现任宇业集团有限公司常务副总裁，江 苏光宇兆能新能源科技有限公司董事长。 2、独立性情况自查说明 本人作为公司独立董事，未在公司兼任除董事会专门委员会主任委员或委 员外的其他职务， ...

Financial Performance - The company's operating revenue for 2024 was CNY 1,175,401,780.87, a decrease of 15.41% compared to CNY 1,389,601,286.62 in 2023[22] - The net profit attributable to shareholders of the listed company was CNY -14,587,166.58, compared to CNY 61,206,384.07 in the previous year, indicating a significant decline[22] - The net profit after deducting non-recurring gains and losses was CNY -38,089,846.38, down from CNY 37,693,074.00 in 2023[22] - The cash flow from operating activities was CNY 192,778,247.22, a decrease of 22.01% from CNY 247,182,519.46 in the previous year[22] - The total assets at the end of 2024 were CNY 3,524,394,269.57, down 4.61% from CNY 3,694,821,482.47 in 2023[22] - The net assets attributable to shareholders of the listed company decreased by 0.87% to CNY 1,660,506,874.47 from CNY 1,675,094,041.05 in 2023[22] - The basic earnings per share for 2024 was CNY -0.0494, compared to CNY 0.2075 in 2023, indicating a shift to negative earnings[23] - The weighted average return on net assets was -0.87% for 2024, down from 3.67% in the previous year[23] Revenue Breakdown - Pharmaceutical business revenue was ¥790,630,187.56, down 20.54% year-on-year, while medical device revenue increased by 14.57% to ¥82,574,608.46[61] - The commercial operations segment generated revenue of ¥188,341,918.76, a decline of 12.94% year-on-year[61] - The exhibition business reported revenue of ¥70,245,750.09, reflecting a growth of 3.81% year-on-year[61] - Revenue from the digestive system segment was CNY 123.51 million, down 57.55% year-over-year, with a gross margin of 81.89%[104] - Revenue from the respiratory segment was CNY 227.76 million, down 3.12% year-over-year, with a gross margin of 61.90%[104] - Revenue from the anti-infection segment was CNY 183.31 million, down 16.53% year-over-year, with a gross margin of 14.42%[104] Market Trends and Strategy - The medical device market in China is projected to grow from 630 billion RMB in 2015 to 1.88 trillion RMB by 2025, with an annual compound growth rate of 11.5%[36] - The domestic market share of domestic brands in high-value consumables, such as artificial joints, increased by 19 percentage points from the first procurement to the 2024 renewal[36] - The company is advancing its "big health + big business" dual business strategy, emphasizing cost control and efficiency improvement[30] - The company is focusing on innovation and market expansion in response to the structural changes in the pharmaceutical industry, particularly in the demand for innovative drugs[130] Research and Development - The company has published 5 papers and presented 36 academic conference papers during the reporting period, indicating a commitment to research and development[31] - The company has a comprehensive R&D platform, with ongoing clinical trials for its innovative drugs expected to yield results by 2025[58] - The company is conducting Phase II clinical trials for the innovative drug DDCI-01, targeting pulmonary arterial hypertension and benign prostatic hyperplasia[105] - Total R&D investment for the year was CNY 45.09 million, with an expense ratio of 3.84% of revenue[112][115] Operational Developments - The company completed the resumption of production for 19 varieties across 9 production lines, resulting in 13 products being launched and sold during the reporting period[30] - The company is actively promoting the construction of new hospital facilities to enhance patient care environments[31] - The company has opened 3 shopping centers and 1 specialty store in Wuhan, with a total area of 35.37 thousand square meters[84] Governance and Management - The company has established a governance structure that complies with relevant laws and regulations, ensuring equal rights for all shareholders, particularly minority shareholders[147] - The board of directors consists of 9 members, including 3 independent directors, and has established four specialized committees to enhance governance and oversight[148] - The company has implemented measures to avoid potential competition with its controlling shareholder by entering into a management contract for the operation of exhibition venue assets[149] - The company has a total of 44,256,815 shares under the employee stock ownership plan, indicating a commitment to employee engagement and retention[155] Environmental Responsibility - The company has established a mechanism for environmental protection and is classified as a key pollutant discharge unit[189] - The wastewater treatment process includes "high-concentration water regulation, mixed air flotation, hydrolysis acidification, secondary contact oxidation, activated sludge, contact oxidation, flocculation sedimentation, and artificial wetland," ensuring compliance with relevant environmental standards[192] - The company has improved its environmental management system, integrating environmental protection into daily operations and enhancing overall awareness among employees[197] Challenges and Risks - The company acknowledges high risks in R&D innovation, including high costs, long cycles, and low success rates, and plans to enhance risk management strategies to improve success rates in new drug and medical device development[144] - The company is closely monitoring industry policy changes to mitigate operational risks associated with drug production costs and profitability due to reforms in the pharmaceutical and medical device sectors[142]

Financial Performance - The company's operating revenue for Q1 2025 was CNY 257,418,265.66, a decrease of 23.51% compared to CNY 336,558,236.01 in the same period last year[5] - Net profit attributable to shareholders was CNY 2,761,438.28, down 78.21% from CNY 12,671,739.22 year-on-year[5] - Basic earnings per share decreased by 78.14% to CNY 0.0094 from CNY 0.0430 in the same period last year[5] - Total operating revenue for Q1 2025 was ¥257.42 million, a decrease of 23.4% compared to ¥336.56 million in Q1 2024[26] - Net profit for Q1 2025 was ¥1.23 million, a decline of 87.3% from ¥9.62 million in Q1 2024[27] - The total comprehensive income for Q1 2025 was ¥1.23 million, a significant drop from ¥9.63 million in Q1 2024[27] Cash Flow - The net cash flow from operating activities was negative CNY 4,350,064.43, a decline of 107.95% compared to CNY 54,745,928.03 in the previous year[5] - Operating cash flow for Q1 2025 was negative at -¥4.35 million, compared to positive cash flow of ¥54.75 million in Q1 2024[30] - Cash inflow from operating activities totaled 194,882,122.09, compared to 263,062,501.37 in the same period last year, indicating a decrease of about 26%[40] - Cash outflow from operating activities was 178,895,582.44, down from 224,010,554.00, reflecting a reduction of approximately 20%[40] - The cash flow from financing activities for Q1 2025 was CNY 61,692,723.15, a significant improvement from a net cash outflow of CNY 51,657,920.84 in Q1 2024[31] - The net cash flow from financing activities was 42,356,460.48, a significant improvement compared to -49,062,450.57 in the previous year[41] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,606,523,833.04, an increase of 2.33% from CNY 3,524,394,269.57 at the end of the previous year[6] - The company's total liabilities increased to ¥1.80 billion in 2025 from ¥1.72 billion in 2024, reflecting a growth of 4.5%[23] - The company's total current liabilities reached CNY 1,498,629,755.67, up from CNY 1,428,511,817.17, which is an increase of approximately 4.9%[22] - The company's total assets as of March 31, 2025, amounted to CNY 2,785,516,683.11, up from CNY 2,756,353,497.56 at the end of 2024[34] - The company's total liabilities increased to CNY 1,094,933,122.23 as of March 31, 2025, compared to CNY 1,067,369,267.77 at the end of 2024[34] Investments and Expenses - Research and development expenses for Q1 2025 were ¥9.33 million, an increase of 29.9% compared to ¥7.18 million in Q1 2024[26] - The company reported a decrease in sales expenses to ¥32.31 million in Q1 2025 from ¥81.07 million in Q1 2024, a reduction of 60.1%[26] - The company reported a decrease in operating costs to CNY 7,915,401.95 in Q1 2025 from CNY 8,838,734.50 in Q1 2024, reflecting a cost reduction strategy[37] - The company’s cash outflow from investment activities totaled CNY 24,556,560.71 in Q1 2025, compared to CNY 62,612,081.33 in Q1 2024, indicating a reduction in investment spending[31] Shareholder Information - The company had a total of 16,547 common shareholders at the end of the reporting period[10] - Total equity attributable to shareholders rose slightly to ¥1.66 billion in 2025 from ¥1.66 billion in 2024, indicating a marginal increase of 0.05%[23] Legal and Compliance - The company has several accounts frozen due to legal issues, with a total balance of CNY 379,986.58 in one account as of March 31, 2025, which may impact liquidity[17] - The company has not adopted new accounting standards or interpretations starting from 2025[41]